CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

被引：5
|
作者：
Messori, Andrea [1 ]
Damuzzo, Vera [2 ]
Leonardi, Luca [3 ]
Agnoletto, Laura [3 ]
Chiumente, Marco [3 ]
Mengato, Daniele [3 ]
机构：
[1] Reg Hlth Serv, HTA Unit, Via San Salvi 12, I-50135 Florence, Italy
[2] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Sch Hosp Pharm, Padua, Italy
[3] Italian Soc Clin Pharm & Therapeut, Sci Direct, Milan, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 07期
关键词：
TIME;
D O I：
10.1016/j.clml.2020.02.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：490 / 491
页数：2
相关论文
共 50 条
  • [1] Feasibility of CAR-T in very old patients with relapsed/refractory diffuse large B-cell lymphoma
    Rozental, Alon
    Chavez, Julio C.
    Sehovic, Marina
    Locke, Frederick L.
    Lazaryan, Aleksandr
    Nishihori, Taiga
    Khimani, Farhad
    Jain, Michael D.
    Shah, Bijal D.
    Extermann, Martine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Relapsed/refractory large B-cell lymphoma CAR-T cell therapies continue to gain importance in everyday treatment
    Walter, Monika
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (09) : 446 - 448
  • [3] Relapsed/refractory large B-cell lymphoma CAR-T cell therapies continue to gain importance in everyday treatment
    不详
    ACTA HAEMATOLOGICA, 2024, 147 (05) : 612 - 614
  • [4] Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All
    Zelenetz, Andrew D.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (12): : 1764 - 1766
  • [5] Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy
    Perrone, Salvatore
    Lopedote, Paolo
    Levis, Mario
    Di Rocco, Alice
    Smith, Stephen Douglas
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 215 - 232
  • [6] Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy
    Di Rocco, Alice
    Cuneo, Antonio
    Di Rocco, Arianna
    Merli, Francesco
    De Luca, Giulia
    Petrucci, Luigi
    Ansuinelli, Michela
    Penna, Domenico
    Rotondo, Francesco
    Rigolin, Gian Matteo
    Giamo, Mariateresa
    Re, Francesca
    Farcomeni, Alessio
    Martelli, Maurizio
    Foa, Robin
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 828 - 836
  • [7] Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study
    Bramanti, Stefania
    Mannina, Daniele
    Chiappella, Annalisa
    Casadei, Beatrice
    De Philippis, Chiara
    Giordano, Laura
    Navarria, Pierina
    Mancosu, Pietro
    Taurino, Daniela
    Scorsetti, Marta
    Carlo-Stella, Carmelo
    Zinzani, Pierluigi
    Santoro, Armando
    Corradini, Paolo
    BONE MARROW TRANSPLANTATION, 2025, 60 (01) : 32 - 38
  • [8] A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
    Hayashino, K.
    Nishimori, H.
    Fujiwara, K.
    Kondo, K.
    Matsubara, C.
    Terao, T.
    Kitamura, W.
    Kamoi, C.
    Seike, K.
    Fujiwara, H.
    Asada, N.
    Ennishi, D.
    Fujii, K.
    Fujii, N.
    Matsuoka, K-I.
    Maeda, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1602 - S1603
  • [9] Relapsed or refractory diffuse large B-cell Lymphoma CAR-T Cell Therapy is superior to Standard Second-line Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (04) : 231 - 231
  • [10] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Di Rocco, Alice
    Di Rocco, Arianna
    Farcomeni, Alessio
    Petrucci, Luigi
    De Luca, Giulia
    Mazzon, Federico
    Martelli, Maurizio
    Foa, Robin
    BLOOD, 2019, 134
12345